Summarized by Masters of Longevity from Longevity Docs News.
Report on a fusion startup pitching fusion reactors as a new commercial source of medical isotopes, focusing on actinium-225 for targeted radiotherapy.
Key Takeaways
- A fusion neutron might be more valuable for producing medical isotopes than electricity.
- Actinium-225 shortages are limiting development and patient access to alpha-emitter therapies.
- Marathon Fusion's isotope claims depend on unproven reactor models and unverified processes.
